Cargando…

Intranasal Immunization with Recombinant HA and Mast Cell Activator C48/80 Elicits Protective Immunity against 2009 Pandemic H1N1 Influenza in Mice

BACKGROUND: Pandemic influenza represents a major threat to global health. Vaccination is the most economic and effective strategy to control influenza pandemic. Conventional vaccine approach, despite being effective, has a number of major deficiencies including limited range of protection, total de...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Shu, Liu, Zhonghua, Xu, Lili, Li, Li, Mei, Shan, Bao, Linlin, Deng, Wei, Li, Lina, Lei, Rongyue, Xie, Liangzhi, Qin, Chuan, Zhang, Linqi
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098841/
https://www.ncbi.nlm.nih.gov/pubmed/21625486
http://dx.doi.org/10.1371/journal.pone.0019863
_version_ 1782204004117250048
author Meng, Shu
Liu, Zhonghua
Xu, Lili
Li, Li
Mei, Shan
Bao, Linlin
Deng, Wei
Li, Lina
Lei, Rongyue
Xie, Liangzhi
Qin, Chuan
Zhang, Linqi
author_facet Meng, Shu
Liu, Zhonghua
Xu, Lili
Li, Li
Mei, Shan
Bao, Linlin
Deng, Wei
Li, Lina
Lei, Rongyue
Xie, Liangzhi
Qin, Chuan
Zhang, Linqi
author_sort Meng, Shu
collection PubMed
description BACKGROUND: Pandemic influenza represents a major threat to global health. Vaccination is the most economic and effective strategy to control influenza pandemic. Conventional vaccine approach, despite being effective, has a number of major deficiencies including limited range of protection, total dependence on embryonated eggs for production, and time consuming for vaccine production. There is an urgent need to develop novel vaccine strategies to overcome these deficiencies. METHODOLOGY/PRINCIPAL FINDINGS: The major objective of this work was to develop a novel vaccine strategy combining recombinant haemagglutinin (HA) protein and a master cell (MC) activator C48/80 for intranasal immunization. We demonstrated in BALB/c mice that MC activator C48/80 had strong adjuvant activity when co-administered with recombinant HA protein intranasally. Vaccination with C48/80 significantly increased the serum IgG and mucosal surface IgA antibody responses against HA protein. Such increases correlated with stronger and durable neutralizing antibody activities, offering protection to vaccinated animals from disease progression after challenge with lethal dose of A/California/04/2009 live virus. Furthermore, protected animals demonstrated significant reduction in lung virus titers, minimal structural alteration in lung tissues as well as higher and balanced production of Th1 and Th2 cytokines in the stimulated splenocytes when compared to those without C48/80. CONCLUSIONS/SIGNIFICANCE: The present study demonstrates that the novel vaccine approach of combining recombinant HA and mucosal adjuvant C48/80 is safe and effective in eliciting protective immunity in mice. Future studies on the mechanism of action of C48/80 and potential combination with other vaccine strategies such as prime and boost approach may help to induce even more potent and broad immune responses against viruses from various clades.
format Text
id pubmed-3098841
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-30988412011-05-27 Intranasal Immunization with Recombinant HA and Mast Cell Activator C48/80 Elicits Protective Immunity against 2009 Pandemic H1N1 Influenza in Mice Meng, Shu Liu, Zhonghua Xu, Lili Li, Li Mei, Shan Bao, Linlin Deng, Wei Li, Lina Lei, Rongyue Xie, Liangzhi Qin, Chuan Zhang, Linqi PLoS One Research Article BACKGROUND: Pandemic influenza represents a major threat to global health. Vaccination is the most economic and effective strategy to control influenza pandemic. Conventional vaccine approach, despite being effective, has a number of major deficiencies including limited range of protection, total dependence on embryonated eggs for production, and time consuming for vaccine production. There is an urgent need to develop novel vaccine strategies to overcome these deficiencies. METHODOLOGY/PRINCIPAL FINDINGS: The major objective of this work was to develop a novel vaccine strategy combining recombinant haemagglutinin (HA) protein and a master cell (MC) activator C48/80 for intranasal immunization. We demonstrated in BALB/c mice that MC activator C48/80 had strong adjuvant activity when co-administered with recombinant HA protein intranasally. Vaccination with C48/80 significantly increased the serum IgG and mucosal surface IgA antibody responses against HA protein. Such increases correlated with stronger and durable neutralizing antibody activities, offering protection to vaccinated animals from disease progression after challenge with lethal dose of A/California/04/2009 live virus. Furthermore, protected animals demonstrated significant reduction in lung virus titers, minimal structural alteration in lung tissues as well as higher and balanced production of Th1 and Th2 cytokines in the stimulated splenocytes when compared to those without C48/80. CONCLUSIONS/SIGNIFICANCE: The present study demonstrates that the novel vaccine approach of combining recombinant HA and mucosal adjuvant C48/80 is safe and effective in eliciting protective immunity in mice. Future studies on the mechanism of action of C48/80 and potential combination with other vaccine strategies such as prime and boost approach may help to induce even more potent and broad immune responses against viruses from various clades. Public Library of Science 2011-05-20 /pmc/articles/PMC3098841/ /pubmed/21625486 http://dx.doi.org/10.1371/journal.pone.0019863 Text en Meng et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Meng, Shu
Liu, Zhonghua
Xu, Lili
Li, Li
Mei, Shan
Bao, Linlin
Deng, Wei
Li, Lina
Lei, Rongyue
Xie, Liangzhi
Qin, Chuan
Zhang, Linqi
Intranasal Immunization with Recombinant HA and Mast Cell Activator C48/80 Elicits Protective Immunity against 2009 Pandemic H1N1 Influenza in Mice
title Intranasal Immunization with Recombinant HA and Mast Cell Activator C48/80 Elicits Protective Immunity against 2009 Pandemic H1N1 Influenza in Mice
title_full Intranasal Immunization with Recombinant HA and Mast Cell Activator C48/80 Elicits Protective Immunity against 2009 Pandemic H1N1 Influenza in Mice
title_fullStr Intranasal Immunization with Recombinant HA and Mast Cell Activator C48/80 Elicits Protective Immunity against 2009 Pandemic H1N1 Influenza in Mice
title_full_unstemmed Intranasal Immunization with Recombinant HA and Mast Cell Activator C48/80 Elicits Protective Immunity against 2009 Pandemic H1N1 Influenza in Mice
title_short Intranasal Immunization with Recombinant HA and Mast Cell Activator C48/80 Elicits Protective Immunity against 2009 Pandemic H1N1 Influenza in Mice
title_sort intranasal immunization with recombinant ha and mast cell activator c48/80 elicits protective immunity against 2009 pandemic h1n1 influenza in mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098841/
https://www.ncbi.nlm.nih.gov/pubmed/21625486
http://dx.doi.org/10.1371/journal.pone.0019863
work_keys_str_mv AT mengshu intranasalimmunizationwithrecombinanthaandmastcellactivatorc4880elicitsprotectiveimmunityagainst2009pandemich1n1influenzainmice
AT liuzhonghua intranasalimmunizationwithrecombinanthaandmastcellactivatorc4880elicitsprotectiveimmunityagainst2009pandemich1n1influenzainmice
AT xulili intranasalimmunizationwithrecombinanthaandmastcellactivatorc4880elicitsprotectiveimmunityagainst2009pandemich1n1influenzainmice
AT lili intranasalimmunizationwithrecombinanthaandmastcellactivatorc4880elicitsprotectiveimmunityagainst2009pandemich1n1influenzainmice
AT meishan intranasalimmunizationwithrecombinanthaandmastcellactivatorc4880elicitsprotectiveimmunityagainst2009pandemich1n1influenzainmice
AT baolinlin intranasalimmunizationwithrecombinanthaandmastcellactivatorc4880elicitsprotectiveimmunityagainst2009pandemich1n1influenzainmice
AT dengwei intranasalimmunizationwithrecombinanthaandmastcellactivatorc4880elicitsprotectiveimmunityagainst2009pandemich1n1influenzainmice
AT lilina intranasalimmunizationwithrecombinanthaandmastcellactivatorc4880elicitsprotectiveimmunityagainst2009pandemich1n1influenzainmice
AT leirongyue intranasalimmunizationwithrecombinanthaandmastcellactivatorc4880elicitsprotectiveimmunityagainst2009pandemich1n1influenzainmice
AT xieliangzhi intranasalimmunizationwithrecombinanthaandmastcellactivatorc4880elicitsprotectiveimmunityagainst2009pandemich1n1influenzainmice
AT qinchuan intranasalimmunizationwithrecombinanthaandmastcellactivatorc4880elicitsprotectiveimmunityagainst2009pandemich1n1influenzainmice
AT zhanglinqi intranasalimmunizationwithrecombinanthaandmastcellactivatorc4880elicitsprotectiveimmunityagainst2009pandemich1n1influenzainmice